Gleevec (imatinib) for a certain kind of stomach cancer
October 2002
Novartis is now promoting Gleevec (imatinib) for a certain kind of stomach cancer.
Gleevec hit the market last year for chronic myeloid leukemia.
Now it's approved for gastrointestinal stromal tumours (GIST). These tumours are rare...but HIGHLY resistant to conventional chemo.
Get concise advice on drug therapy, plus unlimited access to CE
Pharmacist's Letter Canada includes:
- 12 issues every year, with brief articles about new meds and hot topics
- 200+ CE courses, including the popular CE-in-the-Letter
- Quick reference drug comparison charts
- Access to the entire archive